What Oaktree Specialty Lending (OCSL) Said on Its Q4 Earnings Call

Oaktree Specialty Lending logo with Finance background
Image from MarketBeat Media, LLC.

Key Points

  • Adjusted net investment income declined to $29.6 million, or $0.34 per share, in Q4, and to $131.7 million for fiscal 2026, as lower average portfolio balances and reference rates weighed on income. NAV per share edged down to $15.63, and OCSL declared a $0.32 quarterly dividend.
  • Credit quality improved year over year: non-accruals fell to 1.8% of the debt portfolio’s fair value from a year earlier, with six companies on non-accrual versus 10. Oaktree said proceeds and investments returning to accrual drove most of the decline.
  • Q4 investment commitments were $179 million, while repayments and other proceeds totaled $198 million; management said its priority is deploying capital into attractive performing assets and resolving troubled investments. The company ended the quarter with 1.00x net debt-to-equity and about $1.04 billion in liquidity.
  • MarketBeat previews top five stocks to own in December.

Oaktree Specialty Lending NASDAQ: OCSL reported lower adjusted net investment income for its fiscal fourth quarter and full year, as a smaller average portfolio weighed on investment income. The lender said it plans to focus on resolving troubled investments and putting capital to work in performing assets.

Adjusted net investment income for the quarter ended September 30, 2026, fell to $29.6 million, or $0.34 per share, from $32.2 million, or $0.37 per share, in the preceding quarter. President Matt Pendo attributed the decline primarily to a lower average portfolio balance and a higher income-based incentive fee.

For fiscal 2026, adjusted net investment income declined to $131.7 million, or $1.49 per share, from $151.3 million, or $1.76 per share, a year earlier. Adjusted total investment income fell to $281.4 million from $315.4 million, primarily because of lower reference rates and a lower average portfolio balance, CFO and Treasurer Chris McKown said.

The board declared a total quarterly cash dividend of $0.32 per share, comprising a $0.30 base dividend and a $0.02 supplemental dividend. It is payable December 31, 2026, to shareholders of record on December 15. Net asset value per share declined to $15.63 at September 30 from $15.70 at the end of June.

Non-Accruals Decline From a Year Earlier

Non-accrual investments represented approximately 1.8% of the debt portfolio at fair value at fiscal year-end, down about 120 basis points from a year earlier and relatively unchanged from June, Pendo said. Their fair value fell to $45 million from $81 million over the year.

Pendo said nearly 85% of the decline in non-accrual dollars came from proceeds received and investments returning to accrual status. Six companies were on non-accrual at September 30, compared with 10 a year earlier, according to Co-Chief Investment Officer Raghav Khanna.

Khanna said BayMark came off non-accrual following a lender recapitalization, while an additional Pluralsight loan tranche and a new borrower, BioXcel Therapeutics, were placed on non-accrual. BioXcel entered Chapter 11 in August, and a sale to Teva closed in late October at a value in line with Oaktree’s carrying mark of 83, he said.

Khanna said a subsequent U.S. Food and Drug Administration approval triggered an additional $67.5 million milestone payment to lenders. He said the payment was expected within 30 days and would produce a realized value well above Oaktree’s carrying mark. Separately, the remaining balance of Praxio’s debt was repaid at par in early November, he said.

Investment Activity and Portfolio

New investment commitments totaled $179 million in the fourth quarter, down from $206 million in the preceding quarter. Proceeds from prepayments, exits, other paydowns and sales were $198 million, compared with $263 million in the prior quarter. Khanna said the pipeline had built steadily since late September, with approximately $80 million of new commitments originated in October.

The weighted average yield on new debt investments was 9.6%. The portfolio held investments in 170 companies at September 30, with first-lien senior secured debt representing 79.1% of fair value. Its weighted average debt yield was 9.4%, up from 9.3% in the preceding quarter.

Khanna also highlighted the repayment of Oaktree’s remaining $35 million first-lien term loan position in RumbleOn. The loan was repaid at 101, including an exit fee, in September, a year ahead of its 2027 maturity, he said.

Rates and Capital Allocation

CEO and Co-Chief Investment Officer Armen Panossian said higher short-term rates could benefit investment income, while emphasizing the importance of borrowers’ ability to withstand higher interest costs. About 91% of Oaktree’s debt investments were floating rate, and portfolio companies’ weighted average interest coverage was 2.3 times, he said.

McKown said that, once loans and financing costs fully reset, each 25-basis-point increase in base rates would add a little over half a cent per share per quarter to adjusted net investment income, all else equal.

Oaktree ended the quarter with net debt to equity of 1.00 times and approximately $1.04 billion in liquidity. Liquidity would have been approximately $689 million after the planned repayment of notes maturing in January 2027, Pendo said. In September, the company priced $300 million of unsecured notes due in 2031 with a 7% coupon.

Asked about capital allocation, Pendo said the company’s primary focus is deploying capital into attractive investments. He said management was comfortable increasing leverage within the 0.97-to-1.07-times range in which it operated during fiscal 2026, while the company’s longer-term target remains 0.9 to 1.25 times.

About Oaktree Specialty Lending (NASDAQ:OCSL)

Oaktree Specialty Lending Corporation is a business development company that provides financing to middle-market companies. It is externally managed by Oaktree Fund Advisors, an affiliate of Oaktree Capital Management. The company invests primarily in privately negotiated debt, including first- and second-lien loans, subordinated debt and mezzanine financing. It may also make preferred equity and other equity investments, often alongside its debt investments. Oaktree Specialty Lending focuses mainly on companies in the United States, seeking to provide flexible financing for business growth, acquisitions, recapitalizations and other corporate needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Oaktree Specialty Lending Right Now?

Before you consider Oaktree Specialty Lending, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oaktree Specialty Lending wasn't on the list.

While Oaktree Specialty Lending currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines